Palatin Technologies (PTN)

What Moves the Stock

1. 01Clinical trial data readouts for pipeline assets (PL9643 Phase 2 dry eye results, PL8177 IBD program updates) - binary 30-50% moves typical on positive/negative data
2. 02Partnership announcements with upfront payments and milestone structures - historically $10-50M deals drive 20-40% rallies
3. 03FDA regulatory decisions and IND clearances for new indications - particularly orphan drug designations that enhance commercial potential
4. 04Equity financing announcements and cash runway concerns - dilutive offerings typically trigger 15-25% declines
5. 05Vyleesi commercial performance updates and AMAG Pharmaceuticals partnership status - modest impact given small royalty base
6. 06Royalty payments from Vyleesi (bremelanotide) commercial sales through AMAG Pharmaceuticals partnership (minimal, estimated <$5M annually)
7. 07Potential milestone payments from licensing agreements for pipeline assets including PL9643 (dry eye disease) and PL8177 (inflammatory bowel disease)
8. 08Grant funding and collaborative research agreements (sporadic, non-core)

PTN Chart

My Notes

• High-risk growth and speculative investors seeking binary clinical trial outcomes with 3-5x return potential on positive data.
• Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (pipeline assets are…
• Watch on earnings: Quarterly cash burn rate and ending cash balance (target: maintain 18+ month runway), Clinical trial enrollment milestones and data readout timelines for PL9643 and PL8177 programs, Partnership deal announcements with upfront payment values and milestone potential.